2 Nickerson Street, Suite 101
7 articles with Visus Therapeutics
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for the Treatment of Presbyopia
Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for the Treatment of Presbyopia.
Visus Therapeutics Appoints Ophthalmology Expert David Guyer, M.D., as Chairman of the Board and Welcomes Seasoned Life Sciences Executive Ted Danse as Head of Business Development
Visus Therapeutics Inc. today announced the appointment of ophthalmology and industry expert David Guyer, M.D. as the chairman of the Board
Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and Age-related Macular Degeneration; Secures Exclusive License for Novel Ophthalmic Drug Delivery Technology
Visus Therapeutics Inc. announced it has entered into a worldwide exclusive licensing agreement with Cella Therapeutics to develop an array of investigational ophthalmic therapies to treat glaucoma and age-related macular degeneration, two of the leading causes of blindness globally.
Visus Therapeutics has acquired an additional $20 million in funding to support its mission of developing innovative ophthalmic therapies for people worldwide.
Visus Therapeutics Announces $36 Million Series A Financing to Advance Development of Novel Presbyopia-Correcting Eye Drop
Visus Therapeutics Inc. today announced the close of a $36 million Series A Preferred Stock financing. Johnson & Johnson Innovation - JJDC, Inc. (JJDC), RTW Investments, LP, and Wille AG participated in the round, with additional participation from the Company’s existing shareholders